Showing results (71-80 of 140) with videos related to

Sort By:
Pageof 14
Cancers|December 15, 2019
Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived EfficacyAndreas Schneeweiss, Dagmar Hess, Markus Joerger, et al.
JAMA|February 15, 2017
Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast CancerHope S Rugo, Paula Klein, Susan Anitra Melin, et al.
The Oncologist|February 12, 2020
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs RegistryDebu Tripathy, Adam Brufsky, Melody Cobleigh, et al.
Oncotarget|October 8, 2016
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activityYao Huang, David J Burns, Benjamin E Rich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2018
Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERsSara A Hurvitz, Joyce O'Shaughnessy, Ginny Mason, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast Cancer Research and Treatment|February 28, 2021
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registryPeter A Kaufman, Sara A Hurvitz, Joyce O'Shaughnessy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 8, 2009
Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphomaStephen M Ansell, Sara A Hurvitz, Patricia A Koenig, et al.
Future Oncology (London, England)|November 16, 2022
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancerSara A Hurvitz, Thomas Bachelot, Giampaolo Bianchini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 28, 2019
Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERsMelody Cobleigh, Denise A Yardley, Adam M Brufsky, et al.
Pageof 14